Ipsen Group Overview
- Founded
-
1929
- Status
-
Public
- Employees
-
5,744
- Stock Symbol
-
IPN
- Investments
-
27
- Share Price
-
$91.37
- (As of Thursday Closing)
Ipsen Group General Information
Description
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: Specialty care and Consumer Healthcare. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Commercial Services
Stock Exchange
PAR
Primary Office
- 65, Quai Georges Gorse
- 92100 Boulogne Billancourt
- France
Ipsen Group Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $91.37 | $89.84 | $84.37 - $131.96 | $7.54B | 82.5M | 112K | $9.25 |
Ipsen Group Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 7,634,773 | 7,634,773 | 7,469,472 | 8,328,283 |
| Revenue | 3,545,832 | 3,545,832 | 3,061,920 | 3,014,329 |
| EBITDA | 1,267,661 | 1,267,661 | 903,153 | 186,835 |
| Net Income | 764,474 | 764,474 | 624,672 | (56,756) |
| Total Assets | 5,668,803 | 5,668,803 | 5,304,847 | 4,824,469 |
| Total Debt | 784,742 | 784,742 | 1,071,055 | 1,134,958 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ipsen Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ipsen Group Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, e
Pharmaceuticals
Boulogne Billancourt, France
5,744
As of 2021
00000
00000000000
00000
000000
tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad m
00000 0000000000 00000000
Paris, France
00000
As of 0000
000000000000
000000
tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
000000000000000
Basel, Switzerland
000000
As of 0000
000000000000
Add Comparison
Ipsen Group Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sanofi | Corporation | Paris, France | 00000 | 000000000000 | ||
| 00000000 | Corporation | Basel, Switzerland | 000000 | 000000000000 | ||
| 000000 00000000000 | Corporation | Parma, Italy | 0000 | |||
| 000000000000000 | Corporation | Brentford, United Kingdom | 00000 | 000000000 | ||
| 000000000 | Private Equity-Backed | Milan, Italy | 0000 | 000000000000 |
Ipsen Group Patents
Ipsen Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200383894-A1 | Treatment of moderate to very severe glabellar lines and lateral canthal lines | Pending | 07-Jun-2019 | 00000000000 | |
| GB-201907016-D0 | Screening method to determine suitability for participation in a clinical trial | Ceased | 17-May-2019 | 00000000000 | |
| EP-3911742-A1 | Sortase-labelled clostridium neurotoxins | Pending | 16-Jan-2019 | 00000000 | |
| EP-3890772-A1 | Treatment of symptoms of traumatic brain injury | Pending | 05-Dec-2018 | 00000000000 | |
| EP-3888097-A1 | Dosing calculator for spasticity | Pending | 27-Nov-2018 | G16H20/10 |
Ipsen Group Executive Team (27)
Ipsen Group Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 00000000 | Ipsen Group | Board Member | 000 0000 |
| 0000000 0000000 | Ipsen Group | Board Member & Vice Chairman | 000 0000 |
| 00000 000000 | Self | Board Member | 000 0000 |
| 00000 0000 | Ipsen Group | Chief Executive Officer & Board Member | 000 0000 |
| 00000 00000000 | Ipsen Group | Board Member | 000 0000 |
Ipsen Group Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Ipsen Group Investments & Acquisitions (27)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 27-Jun-2022 | 0000000000 | 00000 | Drug Discovery | 00000 000 |
| 0000 00000000 | 18-Nov-2021 | 00000 0000 | 0000 | Drug Discovery | 00000000 |
| 0000000 | 01-Jan-2021 | 00000 0000 | Drug Discovery | ||
| 0000000 | 15-Jun-2020 | 0000 00000 | 00.000 | Enterprise Systems (Healthcare) | |
| Clementia Pharmaceuticals | 18-Apr-2019 | Merger/Acquisition | 00.000 | Biotechnology | 00000 000 |
Ipsen Group Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Canbex Therapeutics | Drug Discovery | London, United Kingdom | 2005 |
| 00000 000000000000 | Biotechnology | Basking Ridge, NJ | 0000 |
| 00000 00000000 | Venture Capital | Boulogne Billancourt, France |
Ipsen Group Exits (7)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000000 | 16-Feb-2017 | 000000000 | 0000 | Completed |
|
| 00000 000000000000 | 13-Aug-2015 | 00000 00000 00 | 0000 | Completed |
|
| 000000 00000000000 | 13-Aug-2015 | 00000 00000 00 | 0000 | Completed |
|
| 000000 00000000000 | 29-Jul-2013 | 00000 00000 00 | 0000 | Completed |
|
| Inserm Transfert | 12-Jan-2012 | Later Stage VC | 000.00 | Completed |
|